Abstract

This is a new institutional application for participation by the University of California, San Francisco, (UCSF) in the scientific activities of the Cancer and Leukemia Group B. UCSF was an affiliate of the University of California, San Diego, in 1990-91 and was voted provisional status as a main member institution of the Group in the fall of 1991. The Principal Investigator on this application, Dr. Henderson, has been a member of the Group and an active contributor to the Breast Cancer program of the CALGB for over 10 years. He is currently the Chairman of the Breast Cancer Committee and participates in the general scientific direction of the Group through his work with the Executive Committee. Two other members of the UCSF faculty are members of CALGB core committees: Dr. Linker on the Leukemia Committee and Dr. Venook on the GI committee. All three of these investigators serve as chairs or co-chairs of CALGB protocols or protocols soon to be activated. Members of the Departments of Surgery, Radiation Oncology, Pathology, and Epidemiology/Biostatistics have been recruited and have made commitments to participate actively in both the scientific program of the Group and in recruiting patients to Group trials. Eight physicians and the program coordinator/data manager from UCSF attended the spring, 1992, CALGB meeting. We will increase our participation in the core committees of the group during the next five years and will marshall the substantial basic science resources of the medical school for the Correlative Science program of the Group. UCSF has a large cancer population from which to recruit patients for clinical trials, and accrual on CALGB protocols has increased dramatically since the fall of 1991. Our current accrual has been annualized to 72 patients/year. We expect to increase this each year and to reach an accrual of at least 130 patients/ year by the end of the funding period. Four UCSF hospitals (Moffitt-Long, Mt. Zion, San Francisco General, the Veterans Administration Medical Center, San Francisco) and one affiliate (Oakland Naval Hospital) will contribute to this effort.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA060138-02
Application #
2100784
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-07-28
Project End
1998-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143

  Publications

Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Guercio, Brendan J; Sato, Kaori; Niedzwiecki, Donna et al. (2015) Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 33:3598-607
Patel, Jai N; Jiang, Chen; Hertz, Daniel L et al. (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121:1025-31
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Shiovitz, Stacey; Bertagnolli, Monica M; Renfro, Lindsay A et al. (2014) CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147:637-45
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Grant, Barbara W; Jung, Sin-Ho; Johnson, Jeffrey L et al. (2013) A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119:3797-804
Rubenstein, James L; Hsi, Eric D; Johnson, Jeffrey L et al. (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061-8

Showing the most recent 10 out of 90 publications